Cupressus arizonica pollen allergy immunotherapy - Laboratorios Leti

Drug Profile

Cupressus arizonica pollen allergy immunotherapy - Laboratorios Leti

Alternative Names: Cupressus arizonica - Laboratorios Leti; Cupressus arizonica allergen extract - Laboratorios Leti

Latest Information Update: 30 Jun 2016

Price : $50

At a glance

  • Originator Laboratorios LETI
  • Class Allergens; Antiallergics; Tree pollen allergy immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Tree pollen hypersensitivity

Most Recent Events

  • 01 Nov 2015 Phase-II clinical trials in Tree pollen hypersensitivity in Spain (Parenteral) (NCT02512653)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top